Additional Lots of Tylenol, Benadryl and Motrin Recalled Over Musty Smell

Johnson & Johnson has recalled additional lots of over-the-counter drugs that may be contaminated with a wood treatment chemical, which could cause some of the medications to have a musty smell and potentially cause illness.

This is the third expansion of an over-the-counter drug recall that was issued as a result of these problems. The latest recall was announced this week for 21 additional lots of the drugs sold in the U.S., Fiji, Guatemala, Dominican Republic, Puerto Rico, Trinidad & Tobago and Jamaica. It includes lots of Benadry Allergy Ultratab, Children’s Tylenol Meltaways Bubblegum, Motrin IB Caplets, Tylenol PM, and Tylenol Extra Strength in EZ Tablets, Cool Caplets, Rapid Release Gelcaps and Day & Night Value Packs. A full list of lot numbers and brands is available in the FDA announcement.

The original Johnson & Johnson drug recall was issued in December 2009 by its McNeil Consumer Healthcare subsidiary for all lots of Tylenol Arthritis Pain Caplet, 100 count bottles, due to contamination by trace amounts of a chemical called 2,4,6-tribromoanisole, or TBA, which seeped into bottles from wood pallets treated with pesticide. The contaminated drugs had a moldy smell and made some users sick.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

According to McNeil Consumer Healthcare, the new lots were added to the recall as a precaution because they were found to be shipped on the same types of wood pallets that led to the contamination.

Along with a massive children’s liquid medication recall issued by McNeil earlier this year, Johnson & Johnson has faced a number of problems with quality control at their production plants, resulting in warning letters from the FDA and congressional scrutiny.

The children’s drug recall affected 136 million bottles of children’s medications, and resulted in the shutdown of the company’s Ft. Washington, Pennsylvania, plant, and the suspension of the production of all of McNeil’s children medications. Following that recall, the FDA has received nearly 800 complaints, including at least seven reports of deaths associated with the medication. However, the FDA says its investigations so far have not directly linked any of the recalled products to any of the deaths.

Some lawmakers, who have started a congressional investigation into Johnson & Johnson’s drug manufacturing activities, are now pushing for expanded FDA power to force drug recalls to help the agency quickly deal with future drug contamination problems.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.